Allos Therapeutics, Inc.

210 articles about Allos Therapeutics, Inc.

• 

  Novel CAR T Therapies Help Celyad's CMO Bring Hope to Fearful Patients

  9/29/2021

  Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.

• Spectrum Pharmaceuticals, Inc. Completes Acquisition of Allos Therapeutics, Inc.; Effective and Swift Integration Expected to Result in Significant Synergies

  9/6/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics

  9/5/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce That Federal Trade Commission Clears Transaction; Tender Offer for Shares of Allos Common Stock to Expire at 5pm Eastern Time on September 4, 2012

  8/29/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  8/20/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  8/6/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  7/23/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  7/9/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  6/22/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  6/8/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

  5/25/2012

• Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Extension of Previously Announced Tender Offer for Shares of Allos Therapeutics

  5/10/2012

• Allos Therapeutics, Inc. Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe

  4/20/2012

• Spectrum Pharmaceuticals, Inc. Commences Tender Offer for All Outstanding Shares of Allos Therapeutics, Inc.

  4/16/2012

• Spectrum Pharmaceuticals, Inc. Scoops Up Allos Therapeutics, Inc. in Deal Worth $206 Million as Bladder Cancer Drug Fails Phase 3

  4/6/2012

• Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals, Inc.

  4/6/2012

• Allos Therapeutics, Inc. Reports Fourth Quarter and Full Year 2011 Financial Results

  3/7/2012

• Allos Therapeutics, Inc. to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012

  2/21/2012

• Allos Therapeutics, Inc. Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at theEuropean Medicines Evaluation Agency

  1/30/2012